CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis

Rampotas A., Wong Z., Gannon I., Brierley C., Shen Y., Benlabiod C., Chee A., Khan S., Hayder N., Cheung G., Mitsikakou M., Murphy E., Ferrari M., Bulek A., Rodriquez-Romera A., Murphy L., Olijnik A-A., Rodriguez-Justo M., Marty C., Hitchcock I., ROYSTON D., Mead A., Khan AO., Lambert J., Roddie C., Psaila B., Pule M.